Emerging Technologies in Preclinical Toxicology
Preclinical toxicology is undergoing a transformation driven by innovative technologies that enhance data quality, reduce animal usage, and improve predictive accuracy for human safety. These emerging tools include advanced in vitro models, high-content imaging, omics platforms, computational toxicology, and digital pathology.
Three-dimensional (3D) cell cultures, organoids, and microphysiological systems replicate tissue architecture and function more faithfully than traditional monolayer cultures. They allow mechanistic studies of toxicity in human-relevant models, enabling early identification of adverse effects and reducing reliance on animal testing.
High-content imaging combines automated microscopy with quantitative image analysis to assess cellular responses to drugs at multiple levels, including morphology, viability, and signaling pathways. This approach facilitates multiplexed screening and detailed phenotypic profiling.
Omics technologies—genomics, transcriptomics, proteomics, metabolomics—generate comprehensive molecular data that reveal pathways involved in toxicity and identify biomarkers. Integrating multi-omics data helps decipher complex toxicological mechanisms and supports precision toxicology.
Computational toxicology employs in silico models, including quantitative structure-activity relationship (QSAR) analyses and machine learning, to predict chemical hazards and prioritize compounds for testing. These models accelerate risk assessment and optimize resource allocation.
Digital pathology enables whole-slide imaging and AI-based image analysis, improving histopathology throughput and objectivity. Artificial intelligence algorithms assist in lesion detection, classification, and severity grading, enhancing reproducibility.
Together, these technologies are reshaping preclinical toxicology, offering opportunities for more ethical, efficient, and human-relevant safety assessments.